Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Julphar
Covington
Baxter
UBS
Daiichi Sankyo
Fuji
Chubb
Boehringer Ingelheim

Generated: October 22, 2017

DrugPatentWatch Database Preview

Cardinal Health 414 Company Profile

« Back to Dashboard

What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?

CARDINAL HEALTH 414 has six approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

There are twenty-four patent family members on CARDINAL HEALTH 414 drugs in eleven countries and thirty-three supplementary protection certificates in eight countries.

Summary for Applicant: Cardinal Health 414

International Patents:24
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
SODIUM FLUORIDE F-18
sodium fluoride f-18
INJECTABLE;INTRAVENOUS203780-001Jul 30, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Cardinal Health 414
FLUDEOXYGLUCOSE F18
fludeoxyglucose f-18
INJECTABLE;INTRAVENOUS203603-001Nov 13, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Cardinal Health 414
MDP-BRACCO
technetium tc-99m medronate kit
INJECTABLE;INJECTION018107-001Approved Prior to Jan 1, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cardinal Health 414
TECHNETIUM TC 99M SESTAMIBI
technetium tc-99m sestamibi kit
INJECTABLE;INJECTION078809-001Apr 28, 2009APRXNoNo► Subscribe► Subscribe► Subscribe
Cardinal Health 414
AMMONIA N 13
ammonia n-13
INJECTABLE;INTRAVENOUS203700-001Feb 25, 2013APRXNoNo► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Cardinal Health 414

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,545,808Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cardinal Health 414 Drugs

Country Document Number Estimated Expiration
South Korea20170027874► Subscribe
Netherlands300736► Subscribe
European Patent Office1178838► Subscribe
Japan4056701► Subscribe
South Korea101713559► Subscribe
Japan2017066148► Subscribe
Australia5270500► Subscribe
Japan2002544243► Subscribe
Japan2012516328► Subscribe
South Korea101765717► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cardinal Health 414 Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C0033France► SubscribePRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
70036Netherlands► SubscribePRODUCT NAME: CIDOFOVIR,DESGEWENST IN DE VORM VAN EEN ZOUT MET AMMONIA,EEN ALKALIMETAAL OF EEN AMINE; REGISTRATION NO/DATE: EU/1/97/037/001 19970423
90025-1Sweden► SubscribePRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120
90018-6Sweden► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Boehringer Ingelheim
Federal Trade Commission
Cerilliant
McKesson
Argus Health
Healthtrust
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot